skip to main content

HCV NS5A Failure Retreatment — SCE Infectious Diseases MCQ

Instant feedback + full explanation. One question, done properly.

HardHepatitisHCV NS5A Failure RetreatmentSCE Infectious Diseases

A patient with genotype-3 hepatitis C and compensated cirrhosis relapses after sofosbuvir–velpatasvir. Which NHS-commissioned direct-acting antiviral is specifically used as rescue therapy after an NS5A-containing regimen?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Sofosbuvir–velpatasvir–voxilaprevir for 12 weeks

The best answer is “Sofosbuvir–velpatasvir–voxilaprevir for 12 weeks”. The triple regimen adds the protease inhibitor voxilaprevir and is recommended within licence for previously treated infection; genotype 3 with cirrhosis needs expert assessment of resistance and whether ribavirin is added. NICE recommends sofosbuvir–velpatasvir–voxilaprevir within its licence for previously treated chronic hepatitis C.

Reference: NICE TA507: sofosbuvir–velpatasvir–voxilaprevir for chronic hepatitis C: https://www.nice.org.uk/guidance/ta507/chapter/1-Recommendations